Vitamin D3 (Cholecalciferol) supplement to enhance the immune status after vaccine against SARS-CoV2, A randomized, double-blind, placebo-controlled trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20220804008

Enrollment

Registered

2022-08-04

Start date

2022-01-10

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy population SAR-COV2 vaccine, Immunization, Vitamin D supplement

Interventions

Vitamin D 50000 IU per tablet 1 tablet per week for 4 weeks,placebo 1 tablet per week for 4 weeks

Experimental Dietary Supplement,Placebo Comparator Dietary Supplement

Vitamin D supplement,Placebo

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Healthy volunteers

Exclusion criteria

Exclusion criteria: 1.vitamin D supplement allergy 2.Pregnancy and lactation 3.Previous vitamin D supplement 4.Receiving immunosuppressive therapy 5.Comorbidities : Heart/Kidney/Liver disease, autoimmune disease, malignancy

Design outcomes

Primary

Measure	Time frame
IgG antibody to Spike protein and serum neutralizing antibody At week 4 ELISA	—

Secondary

Measure	Time frame
N/A N/A N/A	—

Countries

Thailand

Contacts

Public ContactSongwut Phusawang

Phramongkutklao hospital

sphusawang@gmail.com0656396154

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026